Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Eikon Therapeutics announced the first patient dosed in TeLuRide-008, a global registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for stage 4 non-small cell lung cancer (NSCLC).
TeLuRide-008 is a multicenter, randomized, double-blind, placebo-controlled, adaptive Phase 2/3 study evaluating the safety and efficacy of EIK1001 in stage 4 NSCLC, with up to 750 participants.
It is the second registrational Phase 2/3 trial for EIK1001, following positive Phase 2 data from the TeLuRide-005 trial showing high response rates and manageable safety in advanced NSCLC.
Sources:
Eikon Therapeutics Advances EIK1001 with First Patient ...
Eikon Therapeutics Doses First Patient in Phase 2/3 Trial
Eikon Therapeutics doseia primeiro paciente em estudo de câncer de pulmão Por Investing.com
Eikon Therapeutics Shares Up on First Dose to Patient ...
Eikon Therapeutics Announces Seven Abstracts Accepted ...
A Phase 2/3 Study of EIK1001 in Combination with ...
resiquimod sulfate (EIK1001) / Seven and Eight BioPharma, Eikon ...
NCT07365319 | A Safety and Efficacy Study of EIK1001 in ...
EIKN's TeLuRide-008 Trial: A New Lung Cancer Combo Investors Should Watch